Nadine Krüger

26.3k total citations · 3 hit papers
40 papers, 15.5k citations indexed

About

Nadine Krüger is a scholar working on Infectious Diseases, Epidemiology and Virology. According to data from OpenAlex, Nadine Krüger has authored 40 papers receiving a total of 15.5k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Infectious Diseases, 14 papers in Epidemiology and 5 papers in Virology. Recurrent topics in Nadine Krüger's work include SARS-CoV-2 and COVID-19 Research (20 papers), Virology and Viral Diseases (10 papers) and COVID-19 Clinical Research Studies (10 papers). Nadine Krüger is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (20 papers), Virology and Viral Diseases (10 papers) and COVID-19 Clinical Research Studies (10 papers). Nadine Krüger collaborates with scholars based in Germany, United States and Sweden. Nadine Krüger's co-authors include Markus Hoffmann, Stefan Pöhlmann, Christian Drosten, Marcel A. Müller, Hannah Kleine‐Weber, Georg Herrler, Simon Schroeder, Tanja Herrler, Andreas Nitsche and Tobias S. Schiergens and has published in prestigious journals such as Nature, Cell and PLoS ONE.

In The Last Decade

Nadine Krüger

40 papers receiving 15.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

2020 13.3k citations Markus Hoffmann, Hannah Kleine‐Weber et al. Cell profile →
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

2021 563 citations Markus Hoffmann, Prerna Arora et al. Cell profile →
The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic

2021 557 citations Markus Hoffmann, Nadine Krüger et al. Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nadine Krüger Germany	16	11.7k	3.4k	2.8k	1.5k	1.3k	40	15.5k
Hannah Kleine‐Weber Germany	9	11.5k 1.0×	3.4k 1.0×	2.7k 1.0×	1.5k 1.0×	1.2k 1.0×	12	15.3k
Tobias S. Schiergens Germany	22	9.9k 0.8×	3.2k 0.9×	2.5k 0.9×	1.4k 0.9×	1.2k 1.0×	79	14.6k
Simon Schroeder Germany	8	10.0k 0.9×	3.2k 1.0×	2.4k 0.9×	1.3k 0.9×	1.1k 0.8×	9	13.6k
Markus Hoffmann Germany	32	14.2k 1.2×	3.7k 1.1×	3.7k 1.3×	2.0k 1.3×	1.7k 1.3×	116	18.9k
Tanja Herrler Germany	15	9.9k 0.8×	3.3k 1.0×	3.5k 1.3×	1.6k 1.0×	1.2k 0.9×	40	16.2k
Fang Li China	48	16.3k 1.4×	2.3k 0.7×	4.2k 1.5×	1.6k 1.0×	1.7k 1.4×	148	21.2k
Georg Herrler Germany	49	13.3k 1.1×	3.3k 1.0×	4.0k 1.4×	2.2k 1.4×	3.5k 2.8×	165	20.2k
Jian Shang China	19	7.5k 0.6×	1.5k 0.4×	2.1k 0.8×	863 0.6×	707 0.6×	58	9.7k
Yushun Wan China	18	6.9k 0.6×	1.4k 0.4×	2.2k 0.8×	834 0.5×	714 0.6×	30	9.3k
Lei Shi China	33	7.3k 0.6×	3.6k 1.1×	2.0k 0.7×	856 0.6×	1.4k 1.1×	122	12.2k

Countries citing papers authored by Nadine Krüger

Since Specialization

Citations

This map shows the geographic impact of Nadine Krüger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nadine Krüger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nadine Krüger more than expected).

Fields of papers citing papers by Nadine Krüger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nadine Krüger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nadine Krüger. The network helps show where Nadine Krüger may publish in the future.

Co-authorship network of co-authors of Nadine Krüger

This figure shows the co-authorship network connecting the top 25 collaborators of Nadine Krüger. A scholar is included among the top collaborators of Nadine Krüger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nadine Krüger. Nadine Krüger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Krüger, Nadine, Stefan Laufer, & Thanigaimalai Pillaiyar. (2025). An overview of progress in human metapneumovirus (hMPV) research: Structure, function, and therapeutic opportunities. Drug Discovery Today. 30(5). 104364–104364. 3 indexed citations

Schäkel, Laura, Nadine Krüger, Katharina Sylvester, et al.. (2024). Nonpeptidic Irreversible Inhibitors of SARS-CoV-2 Main Protease with Potent Antiviral Activity. Journal of Medicinal Chemistry. 67(17). 14986–15011. 5 indexed citations

Hasan, M. Z., Maren Claus, Nadine Krüger, et al.. (2024). SARS-CoV-2 infection induces adaptive NK cell responses by spike protein-mediated induction of HLA-E expression. Emerging Microbes & Infections. 13(1). 2361019–2361019. 7 indexed citations

Chen, Ye, Julianty Angsana, Nadine Krüger, et al.. (2024). LB943 Prediction of super response and drug-free disease control in guselkumab patients using multivariate baseline serum biomarkers: data from part 3 of GUIDE trial. Journal of Investigative Dermatology. 144(8). S165–S165. 1 indexed citations

Gerdes, Sascha, Matthias Hoffmann, K. Asadullah, et al.. (2023). Effectiveness, safety and quality‐of‐life effects of guselkumab and ustekinumab in patients with psoriasis: Week 104 results from the non‐interventional, prospective, German multicentre PERSIST study. Journal of the European Academy of Dermatology and Venereology. 39(S1). 38–49. 8 indexed citations

Krüger, Nadine, et al.. (2023). Development of novel ligands against SARS‐CoV‐2 M^pro enzyme: an in silico and in vitro Study. Molecular Informatics. 42(11). e202300120–e202300120. 1 indexed citations

Sidarovich, Anzhalika, Nadine Krüger, Cheila Rocha, et al.. (2022). Host Cell Entry and Neutralization Sensitivity of SARS-CoV-2 Lineages B.1.620 and R.1. Viruses. 14(11). 2475–2475. 1 indexed citations

Hoffmann, Markus, Heike Hofmann-Winkler, Nadine Krüger, et al.. (2021). SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. Cell Reports. 36(3). 109415–109415. 162 indexed citations

Arora, Prerna, Anzhalika Sidarovich, Nadine Krüger, et al.. (2021). B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination. Cell Reports. 37(2). 109825–109825. 56 indexed citations

10.

Krüger, Nadine, Cheila Rocha, Federico Armando, et al.. (2021). The Upper Respiratory Tract of Felids Is Highly Susceptible to SARS-CoV-2 Infection. International Journal of Molecular Sciences. 22(19). 10636–10636. 16 indexed citations

11.

Hempel, Tim, Nadine Krüger, Lluı́s Raich, et al.. (2021). Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular properties. Chemical Science. 12(38). 12600–12609. 15 indexed citations

12.

Hoffmann, Markus, Prerna Arora, Rüdiger Groß, et al.. (2021). SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell. 184(9). 2384–2393.e12. 563 indexed citations breakdown →

13.

Hoffmann, Markus, Hannah Kleine‐Weber, Simon Schroeder, et al.. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 181(2). 271–280.e8. 13336 indexed citations breakdown →

14.

Hoffmann, Markus, Kirstin Mösbauer, Heike Hofmann-Winkler, et al.. (2020). Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. Nature. 585(7826). 588–590. 302 indexed citations

15.

Spiegel, Martin, Nadine Krüger, Inga Nehlmeier, et al.. (2019). Inhibitors of signal peptide peptidase and subtilisin/kexin-isozyme 1 inhibit Ebola virus glycoprotein-driven cell entry by interfering with activity and cellular localization of endosomal cathepsins. PLoS ONE. 14(4). e0214968–e0214968. 4 indexed citations

16.

Krüger, Nadine, Christian Sauder, Jan Papies, et al.. (2018). Entry, Replication, Immune Evasion, and Neurotoxicity of Synthetically Engineered Bat-Borne Mumps Virus. Cell Reports. 25(2). 312–320.e7. 14 indexed citations

17.

Fu, Yuguang, et al.. (2018). The Sialic Acid Binding Activity of Human Parainfluenza Virus 3 and Mumps Virus Glycoproteins Enhances the Adherence of Group B Streptococci to HEp-2 Cells. Frontiers in Cellular and Infection Microbiology. 8. 280–280. 14 indexed citations

18.

Hoffmann, Markus, Nadine Krüger, Paweł Zmora, et al.. (2016). The Hemagglutinin of Bat-Associated Influenza Viruses Is Activated by TMPRSS2 for pH-Dependent Entry into Bat but Not Human Cells. PLoS ONE. 11(3). e0152134–e0152134. 22 indexed citations

19.

Alabi, Abraham, Brita Auste, Sandra Eßbauer, et al.. (2016). Human Infections by Non–Rodent-Associated Hantaviruses in Africa. The Journal of Infectious Diseases. 214(10). 1507–1511. 29 indexed citations

20.

Hofmann, Ute, Andreas Busjahn, G Franke, et al.. (2009). Genetic Influences on the Pharmacokinetics of Orally and Intravenously Administered Digoxin as Exhibited by Monozygotic Twins. Clinical Pharmacology & Therapeutics. 86(6). 605–608. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact